Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Ocular Therapeutix, Inc. before investing.

In this article, we go over a few key elements for understanding Ocular Therapeutix, Inc.’s stock price such as:

• Ocular Therapeutix, Inc.’s current stock price and volume
• Why Ocular Therapeutix, Inc.’s stock price changed recently
• Upgrades and downgrades for OCUL from analysts
• OCUL’s stock price momentum as measured by its relative strength

About Ocular Therapeutix, Inc. (OCUL)

Before we jump into Ocular Therapeutix, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Want to learn more about Ocular Therapeutix, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ocular Therapeutix, Inc..

Ocular Therapeutix, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Ocular Therapeutix, Inc.’s stock price was $8.170.

Ocular Therapeutix, Inc. is down 3.54% from its previous closing price of $8.470.

During the last market session, Ocular Therapeutix, Inc.’s stock traded between $8.150 and $8.560. Currently, there are approximately 224.10 million shares outstanding for Ocular Therapeutix, Inc..

Ocular Therapeutix, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Ocular Therapeutix, Inc. Stock Price History

Ocular Therapeutix, Inc.’s (OCUL) price is currently down 16.8% so far this month.

During the month of July, Ocular Therapeutix, Inc.’s stock price has reached a high of $10.940 and a low of $8.150.

Over the last year, Ocular Therapeutix, Inc. has hit prices as high as $16.440 and as low as $6.230. Year to date, Ocular Therapeutix, Inc.’s stock is down 32.7%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Ocular Therapeutix, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there was 1 analyst who downgraded Ocular Therapeutix, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Ocular Therapeutix, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Ocular Therapeutix, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Ocular Therapeutix, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Ocular Therapeutix, Inc. (OCUL) by visiting AAII Stock Evaluator.

Relative Price Strength of Ocular Therapeutix, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Ocular Therapeutix, Inc. has a weighted four-quarter relative price strength of -11.40%, which translates to a Momentum Score of 21 and is considered to be Weak.

Want to learn more about how Ocular Therapeutix, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Ocular Therapeutix, Inc. Stock Price: Bottom Line

As of July 31, 2026, Ocular Therapeutix, Inc.’s stock price is $8.170, which is down 3.54% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Ocular Therapeutix, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.